重症肌无力（myasthenia gravis，MG）是一种由自身抗体介导的神经肌肉接头障碍性免疫性疾病，现代医学能短期缓解症状，但长期治疗面临药物不良反应、并发症及病情复发。中西医协同干预在MG免疫调节中展现出一定优势。多种中药单体及复方通过多途径、多靶点抑制特异性抗体生成、调节细胞免疫失衡、抑制补体激活及调节细胞因子网络与信号通路，从而改善神经肌肉接头功能并缓解MG症状。另外，中药复方联合西药有助于减少药物不良反应，提高治疗缓解率并改善患者生活质量，为个体化治疗提供新思路，但是中西医协同干预MG的实验和临床研究的层次和水平尚需提高。

Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder mediated by pathogenic autoantibodies. Although modern medicine offers effective short-term symptom control, its long-term treatment is limited by adverse drug reactions, complications, and disease recurrence. Integrated traditional Chinese and western medicine (ICWM) has demonstrated potential advantages in the immunomodulatory treatment of MG. Various traditional Chinese medicine (TCM) monomers and compound prescriptions exert therapeutic effects through multiple mechanisms, including suppression of autoantibody production, regulation of cellular immune imbalance, inhibition of complement activation, and modulation of cytokine networks and signaling pathways. These actions help restore neuromuscular junction function and alleviating MG symptoms. Furthermore, combining TCM with conventional therapies may help reduce adverse reactions, enhance remission rates, and improve the patients' quality of life. This also provides new insights into personalized treatment strategies. However, current experimental and clinical research on ICWM for MG still requires further refinement and standardization to meet higher scientific rigor.